.png)
Ognomy Sleep has raised $20M in Series A financing from Catalyst Investors and Blue Heron Capital.
Sleep apnea affects millions of Americans, yet about 80% remain undiagnosed. For many patients, getting care for sleep apnea has been slow and fragmented. Long wait times and disconnected care that leaves coordination to the patient.
Ognomy Sleep was built to change that. The entire care journey happens virtually, from initial appointment with a sleep clinician to an FDA-cleared home sleep test shipping directly to the patient. No sleep lab visit. No complicated steps. Care that meets people where they are.
Since launching in 2021, Ognomy Sleep has completed 85,000+ patient visits with patients being seen nine times faster than traditional sleep treatment. We operate across all 50 states with insurance coverage spanning more than 200 million people, and self-pay options available for those who need them.
This Series A funding will allow Ognomy Sleep to expand its reach, grow its clinical team, and serve many more patients who are still waiting on answers.
"Sleep apnea care should not require months of waiting or patients having to become project managers of their own diagnosis." — Dr. Daniel Rifkin, President and CEO, Ognomy Sleep
